255 related articles for article (PubMed ID: 17984434)
1. Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.
Ramos R; Moreso F; Borras M; Ponz E; Buades JM; Teixidó J; Morey A; Garcia C; Vera M; Doñate MT; de Arellano MR; Barbosa F; González MT
Perit Dial Int; 2007; 27(6):697-701. PubMed ID: 17984434
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
Evenepoel P; Selgas R; Caputo F; Foggensteiner L; Heaf JG; Ortiz A; Kelly A; Chasan-Taber S; Duggal A; Fan S
Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
[TBL] [Abstract][Full Text] [Related]
3. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.
Liu YL; Lin HH; Yu CC; Kuo HL; Yang YF; Chou CY; Lin PW; Liu JH; Liao PY; Huang CC
Ren Fail; 2006; 28(8):701-7. PubMed ID: 17162430
[TBL] [Abstract][Full Text] [Related]
4. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
5. Sevelamer hydrochloride dose-dependent increase in prevalence of severe acidosis in hemodialysis patients: analysis of nationwide statistical survey in Japan.
Oka Y; Miyazaki M; Matsuda H; Takatsu S; Katsube R; Mori T; Takehara K; Umeda Y; Uno F
Ther Apher Dial; 2014 Feb; 18(1):37-43. PubMed ID: 24499082
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride.
Chen JB; Chiang SS; Chen HC; Obayashi S; Nagasawa M; Hexham JM; Balfour A; Junge G; Akiba T; Fukagawa M
Nephrology (Carlton); 2011 Nov; 16(8):743-50. PubMed ID: 21854503
[TBL] [Abstract][Full Text] [Related]
7. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
Pai AB; Shepler BM
Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
[TBL] [Abstract][Full Text] [Related]
8. Plasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a Cross-Sectional Observational Study.
Guida B; Cataldi M; Riccio E; Grumetto L; Pota A; Borrelli S; Memoli A; Barbato F; Argentino G; Salerno G; Memoli B
PLoS One; 2013; 8(8):e73558. PubMed ID: 24015307
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure].
Suñer M; Guerrero A; Montes R; Rivera M; Ruiz A; Martínez-García M; Pérez-Valdivia MA; Mateos J
Nefrologia; 2004; 24(2):142-8. PubMed ID: 15219089
[TBL] [Abstract][Full Text] [Related]
10. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
[TBL] [Abstract][Full Text] [Related]
12. Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients.
Lin YF; Chen YM; Hung KY; Chu TS; Kan WC; Huang CY; Lin SL; Kao TW; Huang JW; Chiang WC; Yen CJ; Tsai TJ; Wu KD; Wu MS
J Formos Med Assoc; 2010 Sep; 109(9):663-72. PubMed ID: 20863994
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
Nephrol Dial Transplant; 2014 May; 29(5):1053-60. PubMed ID: 24376274
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Prajapati VA; Galani VJ; Shah PR
Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
[TBL] [Abstract][Full Text] [Related]
15. A review article: sevelamer hydrochloride and metabolic acidosis in dialysis patients.
Oka Y; Miyazaki M; Takatsu S; Oohara T; Toda K; Uno F; Matsuda H
Cardiovasc Hematol Disord Drug Targets; 2008 Dec; 8(4):283-6. PubMed ID: 19075639
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.
Ketteler M; Rix M; Fan S; Pritchard N; Oestergaard O; Chasan-Taber S; Heaton J; Duggal A; Kalra PA
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1125-30. PubMed ID: 18450923
[TBL] [Abstract][Full Text] [Related]
17. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
[TBL] [Abstract][Full Text] [Related]
18. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.
Goldsmith DR; Scott LJ; Cvetković RS; Plosker GL
Drugs; 2008; 68(1):85-104. PubMed ID: 18081374
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
Wilkes BM; Reiner D; Kern M; Burke S
Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112
[TBL] [Abstract][Full Text] [Related]
20. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children.
Mahdavi H; Kuizon BD; Gales B; Wang HJ; Elashoff RM; Salusky IB
Pediatr Nephrol; 2003 Dec; 18(12):1260-4. PubMed ID: 14586677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
